Page last updated: 2024-09-05

sb 203580 and pyrazole

sb 203580 has been researched along with pyrazole in 2 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (pyrazole)	Trials (pyrazole)	Recent Studies (post-2010) (pyrazole)
3,489	4	1,137	1,152	0	596

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cederbaum, A; Wu, D	1
Aoki, T; Arai, T; Hayashi, S; Hirokawa, H; Inoue, H; Kainoh, M; Kawai, H; Koga, Y; Meguro, H; Ohno, M; Oshida, K; Suyama, K	1

Other Studies

2 other study(ies) available for sb 203580 and pyrazole

Article	Year
Cytochrome P4502E1 sensitizes to tumor necrosis factor alpha-induced liver injury through activation of mitogen-activated protein kinases in mice. Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:3 Topics: Animals; Anthracenes; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2E1; Glutathione; Hepatocytes; Imidazoles; Lipopolysaccharides; Liver Diseases; MAP Kinase Kinase 4; Mice; Mice, Knockout; Mitochondria, Liver; Mitochondrial Swelling; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Transcription Factor AP-1; Tumor Necrosis Factor-alpha	2008
Design and synthesis of novel p38α MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety. Bioorganic & medicinal chemistry letters, 2012, Aug-01, Volume: 22, Issue:15 Topics: Administration, Oral; Animals; Binding Sites; Crystallography, X-Ray; Cytochrome P-450 Enzyme System; Drug Design; Drug Evaluation, Preclinical; Humans; Imidazoles; Lipopolysaccharides; Liver; Mice; Mitogen-Activated Protein Kinase 14; Naphthalenes; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrazoles; Pyridines; Pyrimidines; Tumor Necrosis Factor-alpha; Urea	2012

Article

Year

Cytochrome P4502E1 sensitizes to tumor necrosis factor alpha-induced liver injury through activation of mitogen-activated protein kinases in mice.

Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:3

Topics: Animals; Anthracenes; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2E1; Glutathione; Hepatocytes; Imidazoles; Lipopolysaccharides; Liver Diseases; MAP Kinase Kinase 4; Mice; Mice, Knockout; Mitochondria, Liver; Mitochondrial Swelling; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Transcription Factor AP-1; Tumor Necrosis Factor-alpha

2008

Design and synthesis of novel p38α MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety.

Bioorganic & medicinal chemistry letters, 2012, Aug-01, Volume: 22, Issue:15

Topics: Administration, Oral; Animals; Binding Sites; Crystallography, X-Ray; Cytochrome P-450 Enzyme System; Drug Design; Drug Evaluation, Preclinical; Humans; Imidazoles; Lipopolysaccharides; Liver; Mice; Mitogen-Activated Protein Kinase 14; Naphthalenes; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrazoles; Pyridines; Pyrimidines; Tumor Necrosis Factor-alpha; Urea

2012